Immucell (ICCC) AI Stock Analysis

• Market Cap: $57.79M
• Dividend Yield: N/A
• Average Volume (3M): 36.43K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.26
• Revenue Growth: 28.29%
• EPS Growth: 87.42%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): 0.16
• Shares Outstanding: 9,037,397
• 10 Day Avg. Volume: 74,917
• 30 Day Avg. Volume: 36,432
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.56
• Enterprise Value/Market Cap: 0.60
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: 0.01
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 66 Neutral
• Price Target: $6.50 ▲(1.56%Upside)

Immucell's overall score reflects strong recent sales growth and operational improvements, underpinned by effective financial management and strategic leadership changes. However, the score is moderated by the company's ongoing profitability challenges and valuation concerns.

Immucell Business Overview & Revenue Model

Company Description

Immucell (ICCC) is a biotechnology company operating in the animal health industry. It focuses on developing, manufacturing, and selling products that provide solutions for the prevention and treatment of diseases in livestock, primarily targeting the dairy and beef cattle markets. The company specializes in creating immune-based products that enhance animal health and productivity, with its flagship product being a first-of-its-kind USDA-licensed scours preventative for newborn calves.

How the Company Makes Money

Immucell generates revenue primarily through the sale of its animal health products, which are marketed to dairy and beef cattle producers. The company's key revenue stream is its First Defense product line, which is designed to prevent scours in newborn calves by providing immediate passive immunity. Immucell also invests in research and development to expand its product offerings and improve existing ones, which contributes to growth in its market share. Additionally, the company may engage in strategic partnerships and collaborations to enhance distribution and increase market penetration, thereby boosting its sales and revenue.

Immucell Financial Statement Overview

Summary

Immucell shows promising revenue growth and a strong equity foundation. However, it faces challenges in sustaining profitability and positive free cash flow. The improvements in operating cash flow are encouraging, but the company must address its profitability issues to enhance its financial health.

Income Statement

The company has demonstrated significant revenue growth, especially noted in the TTM period with a substantial increase in total revenue. However, profitability margins such as EBIT and net profit margins have been negative in recent annual reports, indicating ongoing challenges in achieving operational profitability.

Balance Sheet

The balance sheet shows a solid equity position with relatively moderate leverage, as indicated by a reasonable debt-to-equity ratio. The equity ratio is healthy, reflecting the company's ability to finance its operations through shareholder equity rather than excessive debt.

Cash Flow

The company is generating a positive operating cash flow, especially in the TTM period, which indicates improvement in operational cash generation. However, past periods show negative free cash flow, which raises concerns about the company's ability to sustain capital expenditures and finance operations without external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.09B	26.49M	17.47M	18.57M	19.24M	15.34M
Gross Profit	3.36B	7.94M	4.40M	7.65M	8.66M	6.86M
EBITDA	543.31M	1.04M	-2.50M	349.99K	2.72M	1.65M
Net Income	1.45B	-2.16M	-5.77M	-2.49M	-78.00K	-1.02M
Balance Sheet
Total Assets	45.62B	45.10M	43.81M	44.86M	44.47M	40.35M
Cash, Cash Equivalents and Short-Term Investments	4.60B	3.76M	978.74K	5.79M	10.19M	7.95M
Total Debt	6.01B	15.10M	16.69M	12.48M	10.27M	10.73M
Total Liabilities	12.76B	17.58M	18.82M	14.48M	11.89M	12.08M
Stockholders Equity	28.99B	27.52M	24.99M	30.38M	32.58M	28.27M
Cash Flow
Free Cash Flow	1.24B	-107.82K	-6.57M	-5.52M	-1.65M	-2.76M
Operating Cash Flow	1.57B	357.90K	-4.67M	-1.54M	954.17K	1.32M
Investing Cash Flow	-329.44M	-461.23K	-1.89M	-3.96M	-1.60M	-2.57M
Financing Cash Flow	-400.40M	2.88M	1.75M	1.11M	3.88M	1.91M

Immucell Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICCC, the sentiment is Neutral. The current price of 6.4 is below the 20-day moving average (MA) of 6.55, above the 50-day MA of 6.03, and above the 200-day MA of 4.92, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 49.68 is Neutral, neither overbought nor oversold. The STOCH value of 45.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ICCC.

Immucell Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ICCC	66 Neutral	$57.79M	―	-1.01%	―	28.29%	87.42%
RPTX	54 Neutral	$61.76M	―	-71.64%	―	-98.90%	-177.17%
Sector *	49 Neutral	AU$2.50B	4.42	-64.25%	2.77%	36.51%	13.14%
FBIO	48 Neutral	$55.59M	―	-181.84%	―	-32.11%	88.12%
BNR	48 Neutral	$36.59M	―	-37.15%	―	-0.26%	60.09%
IRD	44 Neutral	$59.66M	―	-229.30%	―	-42.30%	-330.51%

Immucell Corporate Events

ImmuCell Announces CEO Succession Planning Process

On June 25, 2025, ImmuCell Corporation announced the commencement of its CEO succession planning process as current CEO Michael F. Brigham plans to retire by early 2026. The company has begun the search for a new CEO, with the goal of selecting a candidate by the end of the year. Brigham, who has been with ImmuCell since 1989 and served as CEO since 2000, will assist in the transition and continue to serve on the Board of Directors through June 2026. This transition marks a significant moment for ImmuCell as it seeks leadership to continue its growth and innovation in the animal health industry.

Immucell Elects Directors, Rejects Compensation Proposals

Immucell held its 2025 Annual Meeting of Stockholders on June 12, 2025, via remote communication. During the meeting, all seven director nominees were elected, but the proposals to approve the executive compensation program and amend the 2017 Stock Option and Incentive Plan were not approved. However, the selection of Wipfli LLP as the independent registered public accounting firm for 2025 was ratified.

ImmuCell Appoints Timothy Fiori as New CFO

On April 7, 2025, ImmuCell Corporation announced the appointment of Timothy C. Fiori as its new Chief Financial Officer. Mr. Fiori brings 24 years of experience from Idexx Laboratories, where he held various financial and commercial roles. His appointment is seen as a strategic move to enhance ImmuCell’s growth, with expectations for him to improve financial systems and find efficiencies across the business.